FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892089040> ?p ?o ?g. }

• W2892089040 abstract "Abstract Purpose Optimal management of patients with intermediate‐risk lymphocyte‐predominant Hodgkin lymphoma (LPHL) is unclear due to their small numbers in most clinical trials. Children's Oncology Group AHOD0031, a randomized phase III trial of pediatric patients with intermediate‐risk Hodgkin lymphoma (HL), included patients with LPHL. We report the outcomes of these patients and present directions for future therapeutic strategies. Procedure Patients received two cycles of doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE‐PC) followed by response evaluation. Slow early responders were randomized to two additional ABVE‐PC cycles ± two dexamethasone, etoposide, cisplatin, and cytarabine cycles and all received involved field radiotherapy (IFRT). Rapid early responders (RERs) received two additional ABVE‐PC cycles. RERs with complete response (CR) were randomized to IFRT or no further therapy. RERs without CR received IFRT. Results Ninety‐six (5.6%) of 1711 patients on AHOD0031 had LPHL. Patients with LPHL were more likely to achieve RER (93.6% vs. 81.0%; P = 0.002) and CR (74.2% vs. 49.3%; P = 0.000005) following chemotherapy compared with patients with classical HL. Five‐year event‐free survival (EFS) was superior in patients with LPHL (92.2%) versus classical HL (83.5%) ( P = 0.04), without difference in overall survival (OS). Among RERs with CR following chemotherapy ( n = 33), there was no difference in EFS or OS between those randomized to receive or not receive IFRT. Conclusion Children and adolescents with intermediate‐risk LPHL represent ideal candidates for response‐adapted therapy based on their favorable outcomes. The majority of patients treated with the ABVE‐PC backbone achieve RER with CR status and can be treated successfully without IFRT." @default.
• W2892089040 created "2018-09-27" @default.
• W2892089040 creator A5025395169 @default.
• W2892089040 creator A5029125087 @default.
• W2892089040 creator A5042826164 @default.
• W2892089040 creator A5054842219 @default.
• W2892089040 creator A5060210860 @default.
• W2892089040 creator A5061910742 @default.
• W2892089040 creator A5073222794 @default.
• W2892089040 creator A5089358491 @default.
• W2892089040 date "2018-09-14" @default.
• W2892089040 modified "2023-10-14" @default.
• W2892089040 title "Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group" @default.
• W2892089040 cites W1552792631 @default.
• W2892089040 cites W1819862099 @default.
• W2892089040 cites W1874243131 @default.
• W2892089040 cites W1901489729 @default.
• W2892089040 cites W1939504905 @default.
• W2892089040 cites W1970146240 @default.
• W2892089040 cites W1972497571 @default.
• W2892089040 cites W1974702217 @default.
• W2892089040 cites W1983317938 @default.
• W2892089040 cites W2006625003 @default.
• W2892089040 cites W2009389738 @default.
• W2892089040 cites W2009402637 @default.
• W2892089040 cites W2045627979 @default.
• W2892089040 cites W2056545314 @default.
• W2892089040 cites W2060554003 @default.
• W2892089040 cites W2077349663 @default.
• W2892089040 cites W2087797534 @default.
• W2892089040 cites W2092204393 @default.
• W2892089040 cites W2094526171 @default.
• W2892089040 cites W2115919161 @default.
• W2892089040 cites W2128719630 @default.
• W2892089040 cites W2133657022 @default.
• W2892089040 cites W2134144266 @default.
• W2892089040 cites W2142278289 @default.
• W2892089040 cites W2170684315 @default.
• W2892089040 cites W2201879560 @default.
• W2892089040 cites W2261683501 @default.
• W2892089040 cites W2286799569 @default.
• W2892089040 cites W2320687883 @default.
• W2892089040 cites W2340481879 @default.
• W2892089040 cites W2400126805 @default.
• W2892089040 cites W2591381257 @default.
• W2892089040 cites W2614289524 @default.
• W2892089040 cites W2766047668 @default.
• W2892089040 doi "https://doi.org/10.1002/pbc.27375" @default.
• W2892089040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6192844" @default.
• W2892089040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30277639" @default.
• W2892089040 hasPublicationYear "2018" @default.
• W2892089040 type Work @default.
• W2892089040 sameAs 2892089040 @default.
• W2892089040 citedByCount "8" @default.
• W2892089040 countsByYear W28920890402019 @default.
• W2892089040 countsByYear W28920890402020 @default.
• W2892089040 countsByYear W28920890402021 @default.
• W2892089040 countsByYear W28920890402022 @default.
• W2892089040 countsByYear W28920890402023 @default.
• W2892089040 crossrefType "journal-article" @default.
• W2892089040 hasAuthorship W2892089040A5025395169 @default.
• W2892089040 hasAuthorship W2892089040A5029125087 @default.
• W2892089040 hasAuthorship W2892089040A5042826164 @default.
• W2892089040 hasAuthorship W2892089040A5054842219 @default.
• W2892089040 hasAuthorship W2892089040A5060210860 @default.
• W2892089040 hasAuthorship W2892089040A5061910742 @default.
• W2892089040 hasAuthorship W2892089040A5073222794 @default.
• W2892089040 hasAuthorship W2892089040A5089358491 @default.
• W2892089040 hasBestOaLocation W28920890402 @default.
• W2892089040 hasConcept C126322002 @default.
• W2892089040 hasConcept C143998085 @default.
• W2892089040 hasConcept C168563851 @default.
• W2892089040 hasConcept C2776694085 @default.
• W2892089040 hasConcept C2776755627 @default.
• W2892089040 hasConcept C2778041864 @default.
• W2892089040 hasConcept C2778119113 @default.
• W2892089040 hasConcept C2778720950 @default.
• W2892089040 hasConcept C2779338263 @default.
• W2892089040 hasConcept C2779429289 @default.
• W2892089040 hasConcept C71924100 @default.
• W2892089040 hasConcept C90924648 @default.
• W2892089040 hasConceptScore W2892089040C126322002 @default.
• W2892089040 hasConceptScore W2892089040C143998085 @default.
• W2892089040 hasConceptScore W2892089040C168563851 @default.
• W2892089040 hasConceptScore W2892089040C2776694085 @default.
• W2892089040 hasConceptScore W2892089040C2776755627 @default.
• W2892089040 hasConceptScore W2892089040C2778041864 @default.
• W2892089040 hasConceptScore W2892089040C2778119113 @default.
• W2892089040 hasConceptScore W2892089040C2778720950 @default.
• W2892089040 hasConceptScore W2892089040C2779338263 @default.
• W2892089040 hasConceptScore W2892089040C2779429289 @default.
• W2892089040 hasConceptScore W2892089040C71924100 @default.
• W2892089040 hasConceptScore W2892089040C90924648 @default.
• W2892089040 hasFunder F4320337351 @default.
• W2892089040 hasIssue "12" @default.
• W2892089040 hasLocation W28920890401 @default.
• W2892089040 hasLocation W28920890402 @default.
• W2892089040 hasLocation W28920890403 @default.
• W2892089040 hasLocation W28920890404 @default.
• W2892089040 hasOpenAccess W2892089040 @default.

• next